Patient
Case

Patient Case

For the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia as adjunctive therapy to diet

Case study: the high-risk patient with mixed dyslipidemia1

ANTARA is a registered trademark of Lupin Limited.

At Diagnosis Post 3 months
(ANTARA added)
Post
9 months
LDL 93 95 97
HDL 36 45 43
Triglycerides 212 137 140

This pre-diabetic patient was an ideal candidate for ANTARA, along with weight loss and low carb diet encouraged.

References
  1. Data on file. Lupin Pharmaceuticals, Inc.